Supot, Ronie B.
HRN: 15-35-32 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/25/2022
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
11/25/2022
12/02/2022
IV
2.25gms
Q12
Cellulitis W/ Elevated Crea
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes